Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma

• DOI: 10.1007/s00270-014-1012-0
• Publication Date: 2014-11-14T13:09:30Z
• Authors: Michael B. Pitton; Roman Kloeckner; Christian Ruckes; Gesine M. Wirth; Waltraud Eichhorn; Marcus A. Wörns; Arndt Weinmann; Mathias Schrecken...; Peter R. Galle; Gerd Otto; Christoph Dueber
• Keywords: Liver Cancer; Tumor progression

To prospectively compare SIRT and DEB-TACE for treating hepatocellular carcinoma (HCC). From 04/2010–07/2012, 24 patients with histologically proven unresectable N0, M0 HCCs were randomized 1:1 to receive or DEB-TACE. could be repeated once in case of recurrence; while, TACE was every 6 weeks until no viable tumor tissue detected by MRI contraindications prohibited further treatment. Patients followed-up 3 months; the final evaluation 05/2013. Both groups comparable demographics (SIRT: 8males/4females, mean age 72 ± 7 years; TACE: 10males/2females, 71 9 years), initial load (1 patient ≥25 % each group), BCLC (Barcelona Clinic Liver Cancer) stage 12×B; 1×A, 11×B). Median progression-free survival (PFS) 180 days versus 216 (p = 0.6193) a median TTP 371 336 days, respectively 0.5764). OS 592 788 0.9271). Seven died group. Causes death liver failure (n 4 progression cardiovascular events, inconclusive 1 group). No significant differences found PFS, OS, TTP. The lower rate group nullified greater incidence failure. This pilot study is first prospective trial comparing HCC, results can used sample size calculations future studies.